The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Updates on IDH inhibition in AML
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discusses updates from trials of drugs targeting isocitrate dehydrogenase (IDH) for patients with acute myeloid leukemia (AML), at the EHA 2021 meeting. Dr Fathi talks on findings of the IDHENTIFY (AG-221-AML-004) study (NCT02577406) which assess the efficacy and safety of enasidenib (AG-221), an IDH2 inhibitor, versus conventional care regimens in patients with late stage AML. Dr Fathi also describes a study investigating the effects of enasidenib in combination with azacitidine versus enasidenib alone (NCT03383575). Both studies showed an increased overall response rate but no overall advantage in overall survival. Dr Fathi suggests some explanations for this lack of statistically significant results. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
